4-amino-quinazolines

1. Compounds of the formula I

in which

R and R 1 are independently of each other H, A, OR 5 , Hal, N(R 5 ) 2 , NO 2 , CN, C(O)R 2 , CON(R 5 ) 2 , COOR 5 , allyl, CH═CH—COOR 5 , CH═CHCON(R 5 ) 2 , SO 2 A or phenyl, which is unsubstituted or mono-, di- or trisubstituted by A;

R 2 is H;

R 3 is —(CH 2 ) o —Z—(CH 2 ) q —N(R 5 ) 2 ;

R 4 is Ar;

R 5 is H or A;

Y is (CH═CH) n ;

Z is phenylene, cyclohexylene, —NR 5 —, O, —CH(OH)—, —CA 2 - or

A is unbranched or branched alkyl having 1 to 6 carbon atoms;

Ar is phenyl or naphthyl, which is unsubstituted or mono-, di- or trisubstituted by A, OR 5 , CF 3 , OCF 3 , Hal, CN, CHO, COA, COOR 5 , N(R 5 ) 2 , NO 2 , SO 2 N(R 5 ) 2 ;

Hal is F, Cl, Br or I;

n is 1 or 2;

o is 1, 2, 3, 4, 5, 6 or 7; and

q is 1, 2, 3 or 4,

or the pharmaceutically acceptable salts thereof.

2. Compounds of the formula I

in which

R and R 1 are independently of each other H, A, OR 5 , Hal, N(R 5 ) 2 , NO 2 , CN, C(O)R 2 , CON(R 5 ) 2 , COOR 5 , allyl, CH═CH—COOR 5 , CH═CHCON(R 5 ) 2 , SO 2 A or phenyl, which is unsubstituted or mono-, di- or trisubstituted by A;

R 2 and R 3 are independently of each other H, A, cycloalkyl, -Het 3 , —(CH 2 ) o —OR 5 , —(CH 2 ) o —OR 6 , —(CH 2 ) o —Het 1 , —(CH 2 ) o —NR 5 —Het 1 , —(CHA) p -(CH 2 ) o —N(R 5 ) 2 , —(CH 2 ) p —(CHA) p -(CH 2 ) m —Ar, —(CH 2 ) o —Z—(CH 2 ) q —N(R 5 ) 2 ,

provided that R 2 and R 3 are not both H;

or NR 2 R 3 together form a saturated monocyclic heterocyclic radical having 5 to 6 ring members, where 1 or 2 N ring atoms are present and the heterocyclic radical can be mono- or disubstituted by OH, Ar, OAr, arylalkyl;

R 4 is Het 1 ;

R 5 is H or A;

R 6 is benzo[1,3]dioxol-5-yl;

Q is O or S;

Y is (CH═CH) n ;

Z is phenylene, cyclohexylene, —NR 5 —, O, —CH(OH)—, —CA 2 - or

A is unbranched or branched alkyl having 1 to 6 carbon atoms;

Ar is phenyl, naphthyl or biphenyl, which in each case is unsubstituted or mono-, di- or trisubstituted by A, OR 5 , cycloalkyloxy, O—(CH 2 ) p -Ph, CF 3 , OCF 3 , Hal, CN, CHO, COA, COOR 5 , N(R 5 ) 2 , NR 5 —COA, NO 2 , SO 2 N(R 5 ) 2 mor, SO 2 -mor, 5-methyl-3-oxo-2,4-dihydropyrazol-2-yl, naphthyl, Het 2 ;

Het 1 is a saturated, partially or completely unsaturated mono- or bicyclic heterocyclic radical having 5 to 10 ring members, where 1 to 2 N, 1 to 2 S, 1 to 2 O ring atoms, or combinations thereof, are present and which is unsubstituted or mono- or disubstituted wherein each substituent is selected from A, Hal, OR 5 , CF 3 , OCF 3 , N(R 5 ) 2 , carbonyl oxygen, COOR 5 , Het 2 , benzyl and phenyl, wherein benzyl and phenyl are unsubstituted or mono-, di- or trisubstituted by A, OR 5 , CF 3 , OCF 3 , Hal, CN, COOR 5 , N(O) 2 , NO 2 , SO 2 N(R 5 ) 2 ;

Het 2 is an unsaturated mono- or bicyclic heterocyclic radical having 5 to 10 ring members, where 1 to 2 N, 1 to 2 S, 1 to 2 O ring atoms, or combinations thereof, are present, and which is unsubstituted or mono- or disubstituted by A, Hal, OR 5 , CF 3 , OCF 3 , N(R 5 ) 2 , COOR 5 ;

Het 3 is a partially or completely unsaturated mono- or bicyclic heterocyclic radical having 5 to 10 ring members, where 1 or 2 N ring atoms are present, and which is unsubstituted or is mono- or disubstituted by A, Hal, OR 5 , CF 3 , OCF 3 , N(O) 2 , SO 2 A, COOR 5 , or combinations thereof, provided that the heterocyclic radical is not bonded via an N atom;

Hal is F, Cl, Br or I;

mor is morpholin-4-yl;

Ph is phenyl;

n is 1 or 2;

m is 0, 1, 2, 3, 4, 5 or 6;

o is 1, 2, 3, 4, 5, 6 or 7;

p is 0, 1, 2, 3 or 4;

q is 1, 2, 3 or 4;

or the pharmaceutically acceptable salts thereof.

3. A compound which is

a) N′-[2-(2-[2,2′]bithiophenyl-5-yl-vinyl)-6-iodo-quinazolin-4-yl]-N,N-diethyl-propyl-1,3-diamine;

b) (3-aminomethyl-cyclohexylmethyl)-[2-(2-[2,2′]bithiophenyl-5-yl-vinyl)-7-chloro-quinazolin-4-yl]amine;

or the physiologically tolerable salts thereof.